Ziyuglycoside II alleviates cyclophosphamide-induced leukopenia in mice via regulation of HSPC proliferation and differentiation
Ziyuglycoside II (ZGS II) is a major bioactive ingredient of Sanguisorbae officinalis L., which has been widely used for managing myelosuppression or leukopenia induced by chemotherapy or radiotherapy. In the current study, we investigated the pro-hematopoietic effects and underlying mechanisms of Z...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-12-01
|
Series: | Biomedicine & Pharmacotherapy |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332220310544 |
id |
doaj-22c66dbed3984c0dafbf5d9b0d815f8d |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Haihong Fang Xinxu Xie Peng Liu Ying Rao Yaru Cui Shilin Yang Jun Yu Yingying Luo Yulin Feng |
spellingShingle |
Haihong Fang Xinxu Xie Peng Liu Ying Rao Yaru Cui Shilin Yang Jun Yu Yingying Luo Yulin Feng Ziyuglycoside II alleviates cyclophosphamide-induced leukopenia in mice via regulation of HSPC proliferation and differentiation Biomedicine & Pharmacotherapy Ziyuglycoside II Leukopenia Hematopoietic stem and progenitor cells Proliferation RNA-seq |
author_facet |
Haihong Fang Xinxu Xie Peng Liu Ying Rao Yaru Cui Shilin Yang Jun Yu Yingying Luo Yulin Feng |
author_sort |
Haihong Fang |
title |
Ziyuglycoside II alleviates cyclophosphamide-induced leukopenia in mice via regulation of HSPC proliferation and differentiation |
title_short |
Ziyuglycoside II alleviates cyclophosphamide-induced leukopenia in mice via regulation of HSPC proliferation and differentiation |
title_full |
Ziyuglycoside II alleviates cyclophosphamide-induced leukopenia in mice via regulation of HSPC proliferation and differentiation |
title_fullStr |
Ziyuglycoside II alleviates cyclophosphamide-induced leukopenia in mice via regulation of HSPC proliferation and differentiation |
title_full_unstemmed |
Ziyuglycoside II alleviates cyclophosphamide-induced leukopenia in mice via regulation of HSPC proliferation and differentiation |
title_sort |
ziyuglycoside ii alleviates cyclophosphamide-induced leukopenia in mice via regulation of hspc proliferation and differentiation |
publisher |
Elsevier |
series |
Biomedicine & Pharmacotherapy |
issn |
0753-3322 |
publishDate |
2020-12-01 |
description |
Ziyuglycoside II (ZGS II) is a major bioactive ingredient of Sanguisorbae officinalis L., which has been widely used for managing myelosuppression or leukopenia induced by chemotherapy or radiotherapy. In the current study, we investigated the pro-hematopoietic effects and underlying mechanisms of ZGS II in cyclophosphamide-induced leukopenia in mice. The results showed that ZGS II significantly increased the number of total white blood cells and neutrophils in the peripheral blood. Flow cytometry analysis also showed a significant increase in the number of nucleated cells and hematopoietic stem and progenitor cells (HSPCs) including ST-HSCs, MPPs, and GMPs, and enhanced HSPC proliferation in ZGS II treated mice. The RNA-sequencing analysis demonstrated that ZGS II effectively regulated cell differentiation, immune system processes, and hematopoietic system-related pathways related to extracellular matrix (ECM)-receptor interaction, focal adhesion, hematopoietic cell lineage, cytokine-cytokine receptor interaction, the NOD-like receptor signaling pathway, and the osteoclast differentiation pathway. Moreover, ZGS II treatment altered the differentially expressed genes (DEGs) with known functions in HSPC differentiation and mobilization (Cxcl12, Col1a2, and Sparc) and the surface markers of neutrophilic precursors or neutrophils (Ngp and CD177). Collectively, these data suggest that ZGS II protected against chemotherapy-induced leukopenia by regulating HSPC proliferation and differentiation. |
topic |
Ziyuglycoside II Leukopenia Hematopoietic stem and progenitor cells Proliferation RNA-seq |
url |
http://www.sciencedirect.com/science/article/pii/S0753332220310544 |
work_keys_str_mv |
AT haihongfang ziyuglycosideiialleviatescyclophosphamideinducedleukopeniainmiceviaregulationofhspcproliferationanddifferentiation AT xinxuxie ziyuglycosideiialleviatescyclophosphamideinducedleukopeniainmiceviaregulationofhspcproliferationanddifferentiation AT pengliu ziyuglycosideiialleviatescyclophosphamideinducedleukopeniainmiceviaregulationofhspcproliferationanddifferentiation AT yingrao ziyuglycosideiialleviatescyclophosphamideinducedleukopeniainmiceviaregulationofhspcproliferationanddifferentiation AT yarucui ziyuglycosideiialleviatescyclophosphamideinducedleukopeniainmiceviaregulationofhspcproliferationanddifferentiation AT shilinyang ziyuglycosideiialleviatescyclophosphamideinducedleukopeniainmiceviaregulationofhspcproliferationanddifferentiation AT junyu ziyuglycosideiialleviatescyclophosphamideinducedleukopeniainmiceviaregulationofhspcproliferationanddifferentiation AT yingyingluo ziyuglycosideiialleviatescyclophosphamideinducedleukopeniainmiceviaregulationofhspcproliferationanddifferentiation AT yulinfeng ziyuglycosideiialleviatescyclophosphamideinducedleukopeniainmiceviaregulationofhspcproliferationanddifferentiation |
_version_ |
1721432839252082688 |
spelling |
doaj-22c66dbed3984c0dafbf5d9b0d815f8d2021-05-21T04:18:31ZengElsevierBiomedicine & Pharmacotherapy0753-33222020-12-01132110862Ziyuglycoside II alleviates cyclophosphamide-induced leukopenia in mice via regulation of HSPC proliferation and differentiationHaihong Fang0Xinxu Xie1Peng Liu2Ying Rao3Yaru Cui4Shilin Yang5Jun Yu6Yingying Luo7Yulin Feng8State Key Laboratory of Innovative Drug and Efficient Energy-Saving Pharmaceutical Equipment, Jiangxi University of Traditional Chinese Medicine, Nanchang 330006, China; School of Pharmacy, Jiangxi Science & Technology Normal University, Nanchang 330013, ChinaState Key Laboratory of Innovative Drug and Efficient Energy-Saving Pharmaceutical Equipment, Jiangxi University of Traditional Chinese Medicine, Nanchang 330006, ChinaState Key Laboratory of Innovative Drug and Efficient Energy-Saving Pharmaceutical Equipment, Jiangxi University of Traditional Chinese Medicine, Nanchang 330006, ChinaState Key Laboratory of Innovative Drug and Efficient Energy-Saving Pharmaceutical Equipment, Jiangxi University of Traditional Chinese Medicine, Nanchang 330006, ChinaState Key Laboratory of Innovative Drug and Efficient Energy-Saving Pharmaceutical Equipment, Jiangxi University of Traditional Chinese Medicine, Nanchang 330006, ChinaState Key Laboratory of Innovative Drug and Efficient Energy-Saving Pharmaceutical Equipment, Jiangxi University of Traditional Chinese Medicine, Nanchang 330006, China; National Pharmaceutical Engineering Center for Solid Preparation in Chinese Herb Medicine, Jiangxi University of Traditional Chinese Medicine, Nanchang 330004, ChinaDepartment of Physiology and Center for Metabolic Disease Research, Lewis Katz School of Medicine, Temple University, Philadelphia, PA19140, USAState Key Laboratory of Innovative Drug and Efficient Energy-Saving Pharmaceutical Equipment, Jiangxi University of Traditional Chinese Medicine, Nanchang 330006, China; National Pharmaceutical Engineering Center for Solid Preparation in Chinese Herb Medicine, Jiangxi University of Traditional Chinese Medicine, Nanchang 330004, China; Corresponding author.State Key Laboratory of Innovative Drug and Efficient Energy-Saving Pharmaceutical Equipment, Jiangxi University of Traditional Chinese Medicine, Nanchang 330006, China; National Pharmaceutical Engineering Center for Solid Preparation in Chinese Herb Medicine, Jiangxi University of Traditional Chinese Medicine, Nanchang 330004, China; Corresponding author at: No. 56 Yangming Road, Donghu District, Nanchang City, Jiangxi University of Traditional Chinese Medicine, 330006, China.Ziyuglycoside II (ZGS II) is a major bioactive ingredient of Sanguisorbae officinalis L., which has been widely used for managing myelosuppression or leukopenia induced by chemotherapy or radiotherapy. In the current study, we investigated the pro-hematopoietic effects and underlying mechanisms of ZGS II in cyclophosphamide-induced leukopenia in mice. The results showed that ZGS II significantly increased the number of total white blood cells and neutrophils in the peripheral blood. Flow cytometry analysis also showed a significant increase in the number of nucleated cells and hematopoietic stem and progenitor cells (HSPCs) including ST-HSCs, MPPs, and GMPs, and enhanced HSPC proliferation in ZGS II treated mice. The RNA-sequencing analysis demonstrated that ZGS II effectively regulated cell differentiation, immune system processes, and hematopoietic system-related pathways related to extracellular matrix (ECM)-receptor interaction, focal adhesion, hematopoietic cell lineage, cytokine-cytokine receptor interaction, the NOD-like receptor signaling pathway, and the osteoclast differentiation pathway. Moreover, ZGS II treatment altered the differentially expressed genes (DEGs) with known functions in HSPC differentiation and mobilization (Cxcl12, Col1a2, and Sparc) and the surface markers of neutrophilic precursors or neutrophils (Ngp and CD177). Collectively, these data suggest that ZGS II protected against chemotherapy-induced leukopenia by regulating HSPC proliferation and differentiation.http://www.sciencedirect.com/science/article/pii/S0753332220310544Ziyuglycoside IILeukopeniaHematopoietic stem and progenitor cellsProliferationRNA-seq |